The Curious Progression of Hepatitis C

Hepatitis C, a serious infection that is passed between people only by blood-to-blood contact was only given its official name in 1989. Before that, as scientists were trying to determine if it was different from the other types of Hepatitis and if so how, it was simply referred to as non-A or non-B Hepatitis. What an odd name for a disease that currently infects at least four million people in the Untied States and over one hundred and seventy million people globally.

Hepatitis C is an odd one because so much of the time it is not obvious when someone has the infection. Seventy percent of those infected show no symptoms, this makes it very hard to diagnose. It is believed that during the acute stage, the first six months, twenty five percent of people who are infected become uninfected for reasons that no one is able to determine.  This is known as spontaneous viral clearance.

For the other seventy five percent of those infected with the Hepatitis C virus, also now as HCV, it becomes chronic.   The only problem with these figures is that they are a bit of a guess.  The number of people that are lucky enough to have a spontaneous viral clearance could be much higher based on the fact that so many people don't realize that they are infected until the HCV has been around for a long time and symptoms start to show. There are no tests that will be able to tell researchers what the exact figures are at this time.

At one time it was common practice to not treat those who were considered to still be in the acute stage. This was because they hoped that by doing nothing it would just go away.  Recent studies are showing that was wrong and that if Hepatitis C is treated early there is a ninety percent success rate. Not only that but the treatment time is cut in half.

Once passed the infection period of six months the Hepatitis C virus now becomes considered a chronic infection.  Interestingly of those who remain untreated it will take thirty percent of them about twenty years to develop cirrhosis of the liver. The next one third will take another ten years on top of that and the last third will take so long that they will die before the liver develops the cirrhosis. There are upwards of one hundred and fifty thousand new cases of HCV each year in the Untied States. People with HIV are very likely to also be infected with HCV as both diseases have similar transmission requirements. Around seventy percent of all intravenous drug users have Hepatitis C.

Research continues on what can be done to control this very serious infection. Unlike Hepatitis A or B there is currently no vaccine.  But recent studies have made some progress and a new vaccine is in the testing stages with human subjects. So far it is having significantly successful results. The studies are continuing. 

Hepatitis news on the Web

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover - BusinessWeek

RTT News

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Sciences jumps on hepatitis C dataCBS News
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
Gilead shares surge as hep C drug scores a cure for big patient populationFierceBiotech
Lagonian.com -Barron's (blog)
all 63 news articles »

Hepatitis Research May Benefit From Stem Cells - Medical News Today

MD News

Hepatitis Research May Benefit From Stem Cells
Medical News Today
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic ...
Personalized Liver Cells Support Hepatitis C VirusDoctors Lounge
Scientists establish HCV infection in liver-like cells derived from iPSCsNews-Medical.net

all 5 news articles »

Idenix gets good news on hep C trial, but can't compete with Gilead - FierceBiotech

Citybizlist

Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster ...
Idenix Falls Casualty to Gilead Hep C HooplaTheStreet.com
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
FDA removes hold on Idenix hep C drug targetMass High Tech
NASDAQ -Sacramento Bee
all 31 news articles »

HP awards Meg Whitman $16.5 million pay package - San Francisco Chronicle

HP awards Meg Whitman $16.5 million pay package
San Francisco Chronicle
Gilead's shares rose 11 percent on news a hepatitis C drug showed positive results in clinical trials. Gilead Sciences, the Foster City drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in ...

and more »

Vertex Hep C Sales Growth Nears End - TheStreet.com

Vertex Hep C Sales Growth Nears End
TheStreet.com
(TheStreet) -- Vertex Pharmaceuticals'(VRTX) fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch.
Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston MoverBusinessWeek
Vertex shares drop as analyst cools on high-flying hep C drugBoston Business Journal
Vertex Falls as analyst cuts sales estimates on hepatitis C pillBoston Globe
LocalizedUSA
all 15 news articles »

Prosecutor says doctor in hepatitis C outbreak is faking disabilities. - Las Vegas Review - Journal

Washington Examiner

Prosecutor says doctor in hepatitis C outbreak is faking disabilities.
Las Vegas Review - Journal
Desai, 62, is challenging state medical experts who found him competent to stand trial on criminal charges in the 2007 hepatitis C outbreak. » Buy this photo By Jeff German Dr. Dipak Desai, the physician at the center of the hepatitis C outbreak, ...
Judge: Dipak Desai competent to stand trial in hepatitis caseLas Vegas Sun
Desai found competent to stand trialLas Vegas Review-Journal
Ex-doc ruled fit for trial in Vegas hep C caseWashington Examiner

all 15 news articles »

researchers identify peptide that inhibits replication of hepatitis C - UC Los Angeles

researchers identify peptide that inhibits replication of hepatitis C
UC Los Angeles
By Kim Irwin February 02, 2012 Category: Health Sciences, Research Researchers from UCLA's Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide that inhibits a hepatitis C virus protein and blocks the viral replication that can ...

and more »

March trial for Desai may be postponed again - Las Vegas Review - Journal

March trial for Desai may be postponed again
Las Vegas Review - Journal
Buy this photo By Jeff German Dr. Dipak Desai may have been found competent to face criminal charges in the hepatitis C outbreak, but his upcoming March 12 trial is expected to be delayed again. Lawyers on both sides of the massive criminal case do not ...
FOX5 Vegas - KVVUDipak Desai found mentally fit to stand trialKVVU Las Vegas
Ex-doc ruled fit for trial in Vegas hepatitis-C caseMyNews3

all 5 news articles »

Vertex posts 4Q profit on growing Incivek sales - CBS News

Vertex posts 4Q profit on growing Incivek sales
CBS News
Drugmaker Vertex Pharmaceuticals Inc. said Thursday it turned a profit in the fourth quarter on sales of its hepatitis C pill Incivek, which was approved in May. Vertex reported a profit of $158.6 million, or 74 cents per share.
Curing Diseases Makes For a Bad Business ModelDailyFinance
Vertex roiled by fickle marketBizjournals.com
Vertex Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call TranscriptSeeking Alpha
Zacks.com
all 21 news articles »

Stem Cells May Further Hepatitis C Research - U.S. News & World Report

Stem Cells May Further Hepatitis C Research
U.S. News & World Report
31 (HealthDay News) -- Using stem cells to create liver-like cells for laboratory research may advance efforts to find out why people respond differently to hepatitis C infection, scientists say. It's not clear why some people are resistant to ...

and more »


Google News